Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225 Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer.
Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225 Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer.